19:23 , Jan 17, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Parkinson’s disease (PD) In vitro and rat studies suggest co-transplantation of neural progenitor cells (NPCs) and astrocytes expressing NURR1 and FOXA2 could help treat PD. In mouse or rat ventral midbrain-derived NPCs, co-culture with astrocytes...
19:55 , Jan 11, 2018 |  BC Innovations  |  Translation in Brief

Astrocytes on the mind

Stem cell transplants have the potential to replace lost neurons in the brains of Parkinson’s disease patients, but preclinical efficacy results have been disappointing because of poor survival and function of the resulting neurons. To...
19:22 , Sep 19, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Parkinson's disease (PD) Non-human primate studies suggest induced pluripotent stem (iPS) cell-derived dopaminergic neurons could help treat PD. The dopaminergic neurons were generated from iPS cells derived from PD patients or healthy volunteers by inducing...
07:00 , Jun 16, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Forkhead box A1 (FOXA1); FOXA2; FOXA3; GATA binding protein 4 (GATA4); HNF1 homeobox A (HNF1A); hepatocyte nuclear factor 4 α (HNF4A; TCF) FOXA3,

Hepatic disease INDICATION: Liver fibrosis Mouse studies suggest in vivo reprogramming of liver myofibroblasts into hepatocyte-like cells could help treat liver fibrosis. In a mouse model of the disease, in vivo transduction of myofibroblasts with six adeno-associated...
08:00 , Jan 16, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine/metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Diabetes Pancreatic and duodenal homeobox 1 (PDX1; IPF1) In vitro studies identified a small molecule that...
07:00 , Jul 28, 2011 |  BC Innovations  |  Strategy

Foundational strategies in PD therapeutics

The Michael J. Fox Foundation for Parkinson's Research has been playing at all stages of the development spectrum. Most recently it has granted $2.4 million to fund research into repurposing marketed drugs to treat Parkinson's...
08:00 , Dec 17, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine disease Obesity Forkhead box A2 (FOXA2) Studies in mice suggest that increasing FOXA2 expression in the hypothalamus...
08:00 , Jan 3, 2005 |  BC Week In Review  |  Company News

Rockefeller University other research news

Researchers published in Nature that inhibiting the phosphorylation of Foxa2 might be an effective treatment for Type II diabetes. Foxa2 transcription is inhibited in normal mice, but in a fasted low insulin state, Foxa2 activates...
07:00 , Sep 1, 2003 |  BC Week In Review  |  Company News

Sequenom other research news

Researchers reported that the FOXA2 protein, already known to be involved in pancreatic development and islet cell function, is genetically associated with Type II diabetes. Data were presented at the Genomics of Diabetes conference in...
07:00 , Aug 25, 2003 |  BC Extra  |  Clinical News

Sequenom up on diabetes news

SQNM was up $0.34 (13%) to $3.06 on 2.8 million shares on Monday after reporting that the FOXA2 protein, previously known to be involved in pancreatic development and islet cell function, is genetically associated with...